| Description | Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cutting of C5 and preventing the subsequent formation of membrane attack complex, which can be used to study extravascular hemolysis. |
| In vitro | Tesidolumab（LFG316）在人体内的半衰期约为9天。与eculizumab和ravulizumab不同，Tesidolumab（LFG316）绑定到一个远离Arg 885的独特表位上[1]。 |
| Synonyms | LFG316 |
| molecular weight | N/A |
| CAS | 1531594-08-7 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Jun-Ichi Nishimura, et al. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2022 Jun 1;107(6):1483-1488. |